Protalix BioTherapeutics, Inc.
corporate_fare Company Profile
Protalix BioTherapeutics, Inc. (NYSE:PLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for PLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for PLX spans 10-Q, 8-K.
Recent high-impact activity:
- Protalix 10-Q: $26.1M Nine-Month Profit, $48.5M Cash, No Debt
- Protalix Q3 2026: Net Income $4.0M, YTD Revenue $75.6M, 2026 Guidance Reaffirmed
Financial Snapshot
Short Interest & Short Volume
6.18 days to coverFINRA reported short interest of 3,480,033 shares in PLX as of the October 30, 2026 settlement, a 0.8% decrease from the prior period — about 6.2 days to cover at its recent average daily volume. On November 19, 2026, 34.9% of PLX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.